For both, a prompt and durable response to a bradykinin B2 receptor antagonist or another approved HAE on-demand treatment (if available) early in an attack is evidence helping to support the diagnosis of bradykinin-mediated angioedema. Here, BDKRB2 is linked to hereditary angioedema.